AstraZeneca PLC (AZN)vsCosmos Health Inc. (COSM)
AZN
AstraZeneca PLC
$184.45
-0.23%
HEALTHCARE · Cap: $293.73B
COSM
Cosmos Health Inc.
$2.49
-23.15%
HEALTHCARE · Cap: $20.89M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 84514% more annual revenue ($62.38B vs $73.73M). AZN leads profitability with a 17.7% profit margin vs -33.1%. AZN earns a higher WallStSmart Score of 68/100 (B-).
AZN
Strong Buy68
out of 100
Grade: B-
COSM
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.3%
Fair Value
$197.94
Current Price
$184.45
$13.49 discount
Intrinsic value data unavailable for COSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 29.6%
Earnings expanding 23.5% YoY
Generating 4.0B in free cash flow
Revenue surging 28.8% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Trading at 9.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -106.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bull Case : COSM
The strongest argument for COSM centers on Revenue Growth. Revenue growth of 28.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : COSM
The primary concerns for COSM are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while COSM is a growth play — different risk/reward profiles.
COSM carries more volatility with a beta of 4.44 — expect wider price swings.
COSM is growing revenue faster at 28.8% — sustainability is the question.
AZN generates stronger free cash flow (4.0B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (68/100 vs 36/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Cosmos Health Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?